PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-201.62%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-201.62%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-128.59%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-127.78%
Negative EPS growth while GNPX is at 34.62%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-127.78%
Negative diluted EPS growth while GNPX is at 34.62%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
37.70%
OCF growth above 1.5x GNPX's 7.14%. David Dodd would confirm a clear edge in underlying cash generation.
37.70%
FCF growth above 1.5x GNPX's 7.14%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
24.48%
10Y OCF/share CAGR under 50% of GNPX's 91.62%. Michael Burry would worry about a persistent underperformance in cash creation.
24.48%
Below 50% of GNPX's 96.48%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
24.48%
3Y OCF/share CAGR under 50% of GNPX's 96.26%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
9.10%
Below 50% of GNPX's 99.56%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
9.10%
Below 50% of GNPX's 96.58%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
9.10%
Below 50% of GNPX's 96.48%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
-301.87%
Negative equity/share CAGR over 10 years while GNPX stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-301.87%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-301.87%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.07%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-11.47%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
6.41%
Debt growth of 6.41% while GNPX is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
No Data
No Data available this quarter, please select a different quarter.
186.72%
SG&A growth well above GNPX's 52.68%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.